# US 2023/0057598 A1 · Screening kit for paroxysmal supraventricular tachycardia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057598 A1
- Document ID: US20230057598A1
- Status: Published application
- Kind: A1
- Application number: 17/757,911
- Filed: 2020-09-10
- Published: 2023-02-23
- Earliest claimed: 2019-12-23
- Assignees: Sichuan Provincial People's Hospital; Chengdu Medical College; Nanjing Ysy Biotech Company Ltd.
- Applicants: Sichuan Provincial People's Hospital; Chengdu Medical College; Nanjing Ysy Biotech Company Ltd.
- Inventors: Xiaoping LI; Rong LUO; Qingshun ZHAO; Zhenglin YANG; Tao HE; Mingjiang LIU
- Web page: https://patentgrep.com/patent/US20230057598A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6869: Methods for sequencing
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A screening kit for paroxysmal supraventricular tachycardia contains a reagent for detecting a human CACNA1B gene c. 1700A>G mutation site at base No. 1700 in a coding region of CACNA1B gene from A to G.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

Use of a reagent for detecting the c.1700A>G mutation site of human CACNA1B gene in the preparation of a screening kit for atrioventricular nodal reentrant tachycardia, characterized in that the sequence of the human CACNA1B gene is represented by SEQ ID NO: 3.

### Claim 12 (depends on 11)

The use according to claim 11, characterized in that the kit further comprises an optional related reagent for amplifying a genomic DNA fragment comprising the mutation site.

### Claim 13 (depends on 11)

The use according to claim 11, characterized in that said related reagents used to detect the c.1700A>G mutation site of the human CACNA1B gene are those used in sequencing, fluorescent quantitative PCR, restriction fragment length polymorphism methods, or a single-strand conformation polymorphism analysis.